Orgenesis Establishes Belgium Subsidiary for Manufacturing Process Development of Clinical Grade Cells

Marketwired

WHITE PLAINS, NY--(Marketwired - Nov 5, 2013) - Orgenesis, Inc. (OTCQB: ORGS), a development-stage company with a novel regenerative medicine technology that converts a diabetes patient's liver cells into functioning insulin-producing cells, has established and registered a subsidiary in Belgium, named Orgenesis SPRL, to complete process development and enable product manufacturing of cells to be used for clinical trials in Europe. 

The incorporation of Orgenesis SPRL follows a partnership established in May 2013 with ATMI, Inc (NASDAQ: ATMI) for the Integrity® Xpansion™ disposable bioreactors from ATMI LifeSciences to become a major component in Orgenesis' cell culture product manufacturing. Prior to establishing Orgenesis SPRL, Orgenesis began working with key CMOs (contract manufacturing organizations) in Belgium's Walloon region in order to develop a commercially-scalable manufacturing process. The Walloon region has become a central hub to innovative companies addressing new technologies for cell therapy. 

Orgenesis will continue to collaborate with ATMI and other partners in the region to complete tech transfer from their R&D Operations in Tel Aviv and further automate its cell manufacturing process.

"Our recently submitted request to the subsidy program of the Walloon region for funding 70% of Orgenesis SPRL activity until clinical studies commence makes Belgium a natural choice for our cell manufacturing process development activities," said Sav DiPasquale, Chief Executive Officer of Orgenesis. "This initiative geographically aligns our efforts with key partners such as ATMI LifeSciences, and is expected to facilitate our European clinical trial design, enrollment and overall program progression."

About Orgenesis Inc.
Orgenesis (ORGS) is a development stage company with a novel therapeutic technology that employs a molecular and cellular approach directed at converting a patient's own liver cells into functional insulin producing cells, as a treatment for diabetes. Orgenesis believes that converting the diabetic patient's own tissue into insulin-producing cells overcomes the problem of donor shortage and removes the risk of transplant rejection. If successful, this could mean the end of diabetes, as we now know it. For more information visit: www.orgenesis.com.

About ATMI

ATMI, Inc. provides specialty semiconductor materials, and safe, high-purity materials handling and delivery solutions designed to increase process efficiencies for the worldwide semiconductor, flat panel, and life sciences industries. For more information, please visit http://www.atmi.com.

About ATMI LifeSciences

ATMI LifeSciences is an acknowledged technology leader in the field of single-use bioprocess systems and consumables for the pharmaceutical and biopharmaceutical industries. Its innovative, market-leading portfolio of custom-engineered, flexible packaging solutions, single-use storage systems, mixers and bioreactors is driving bioprocess efficiency and delivering value for biopharmaceutical companies around the world. For more information, go to www.atmi-lifesciences.com.

ATMI, Integrity and Xpansion are trademarks, or registered trademarks, of Advanced Technology Materials, Inc., in the United States, other countries or both.

Notice Regarding Forward-Looking Statements

This news release contains "forward-looking statements" which are not purely historical. Such forward-looking statements include, among other things, the expectations of management that our regeneration technology can be developed as therapeutic treatment for diabetes which could, if successful, mean the end of diabetes as we know it; that we have an advantage over competitors with our approach to treating diabetes; Orgenesis will continue to collaborate with ATMI and other partners in the region to complete tech transfer from their R&D Operations in Tel Aviv and further automate its cell manufacturing process; and the expectation of the acceleration of Orgenesis' European clinical trial design, enrollment and overall program progression. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits Orgenesis will obtain from them. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies, which include, without limitation, the potential failure of development candidates to advance through preclinical studies or demonstrate safety and efficacy in clinical testing and the ability to pass clinical trials so as to move on to the next phase;, our ability to retain key employees; our ability to finance development or satisfy the rigorous regulatory requirements for new medical procedures; and competitors may develop better or cheaper alternatives to our products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Investors should refer to the risk factors disclosure outlined in our periodic reports filed from time-to-time with the Securities and Exchange Commission.

Contact:
Company
Sav DiPasquale
President & Chief Executive Officer
416-509-9832
sav.d@orgenesis.com

Investor Relations:
Chris Tyson
Liolios Group, Inc.
Tel (949) 574-3860
ORGS@liolios.com
View Comments (0)